$196.79
24h
-4.84%
30 Sep, 12:56
Citi Downgrades Moderna to Sell on Overvaluation
Bearish-3.28%
AI Summary
The author shares Citi's bearish downgrade of Moderna, highlighting that its recent rally has overstretched valuation relative to achievable cancer drug sales.
Citi downgraded $MRNA to Sell from Neutral, saying the stock’s 222% rally since interim INTerpath-001 cancer trial results has pushed the valuation too far.
The bank raised its price target to $80 from $60, but says Moderna’s roughly $80B market cap now implies success across multiple cancer indications.
Citi estimates that even assuming 100% success for intismeran’s lead programs, its valuation supports only around $100/share.
To justify roughly $200/share, Citi says the drug would need to generate about $26B in annual cancer sales, nearly 7x its current forecast.
Citi still sees intismeran as potentially becoming a leading melanoma treatment, but says investors now need to see strong efficacy and consistency across patient groups.